Overview Financials News + Filings Key Docs Charts Ownership Insiders
|
|
ADIAL PHARMACEUTICALS, INC. (ADIL)
|
|
| Common Size Income Statement |
|
|
|
|
Annual | Quarterly | TTM |
|
| In millions, except per share items | Dec-31-21 | Dec-31-20 | Dec-31-19 | Dec-31-18 | Dec-31-17 | Dec-31-16 | Dec-31-15 |
| | 10-K | 10-K | 10-K | 10-K | 10-K | S-1 | S-1/A |
| Revenues | 100.0% | | | 100.0% | 100.0% | | |
| Cost of goods sold | 0.0% | | | -182932.6% | 100.0% | | |
| Gross profit | 100.0% | | | 183032.6% | 0.0% | | |
| Research and development | 42.5% | | | 7946.1% | 5176.4% | | |
| General and administrative | 47.3% | | | 142738.0% | 23114.8% | | |
| EBITDA | -87.5% | | | -150672.0% | -28275.2% | | |
| Depreciation | 0.0% | | | | | | |
| EBITA | -87.5% | | | -150672.0% | -28275.2% | | |
| Amortization of intangibles | 0.0% | | | 12.1% | 16.1% | | |
| EBIT | -87.5% | | | -150684.1% | -28291.2% | | |
| Pre-tax income | -98.9% | | | -250838.4% | -32389.3% | | |
| Income taxes | -0.5% | | | 0.0% | 0.0% | | |
| Net income | -98.4% | | | -250838.4% | -32389.3% | | |
|